The Lancet Infectious Diseases
|
|
|
- Lucy Leonard
- 5 years ago
- Views:
Transcription
1 Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al The Lancet Infectious Diseases DOI: /S (17)
2 Background ~10 4 Mio new tuberculosis cases in 2015, but only 6 1 Mio (59%) diagnosed ~ Rif-resistant cases, only (20%) identified GeneXpert (WHO endorsed since 2010) WHO Meta-Analysis PTB sensitivity/specificity: 88% / 99% Detection Rifampicin resistance PTB: 95% / 98%1 LNTB: 85% / 93% CSF: 80% / 99% Pleura: 44% 98% Gastric lavage: 84% / 98% 1 compared to culture as reference standard;
3 GeneXpert GeneXpert MTB/RIF Ultra according to manufacturer: - Higher sensitivity in smear-neg cases - Increased accuracy in detection of rifampicin resistance - Results in <80 minutes
4 Objectives & Hypothesis to estimate and compare the sensitivity of a single Xpert Ultra test with that of a single Xpert test of the same raw sputum specimen for detection of smear- negative tuberculosis and rifampicin resistance to estimate and compare Xpert Ultra and Xpert specificities for detection of rifampicin resistance. Hypothesis: Sensitivity of Ultra-Xpert non-inferior to sensitivity of Xpert in smear-negative PTB 8 countries: South Africa, Uganda, Kenya, India, China, Georgia, Belarus, Brazil
5 Procedures Case-detection group: PTB symptoms and no TB Rx since > 6 months MDR risk group: microbiologically confirmed pulmonary tuberculosis with documented rifampicin resistance and tuberculosis treatment received for 31 days or less known pulmonary tuberculosis with suspected treatment failure history of drug-resistant tuberculosis and off tuberculosis treatment for at least 3 months Goldstandard: Culture MPT64/MPB64 antigen detection Phenotypic DST
6 Definitions Culture-positive: 1 culturepositive Smear-positive: 1 smear positive Culture-negative: 2 negative cultures Sputum-collection: 3 (4) sputum on 2 consecutive days Xpert/U-Xpert on 1st sputum (index-sputum) Sample-size: Non-inferiority margin Xpert Ultra versus Xpert (smear-neg TB): 7% Non-inferiority margin Xpert Ultra versus Xpert (sens/spec Rif Res): 3%
7
8 248 excluded from analysis* 4 missing data to be classified into enrolment group 39 non-determinate Xpert result 79 non-determinate Xpert Ultra result 1 missing Xpert and Xpert Ultra results 114 missing or outstanding complete case definition 25 smear-positive with all cultures negative 1753 participants included in the analyses 1439 participants in case detection group 462 culture-positive 323 culture-positive and smear-positive 137 culture-positive and smear-negative 2 smear result missing 977 culture-negative 314 participants in multidrug resistance risk group 215 culture-positive 172 culture-positive and smear-positive 43 culture-positive and smear-negative 99 culture-negative
9 Sensitivity and specificity of Xpert Ultra
10 Detection of Rifampicin Resistance Detection of rifampicin resistance Sensitivity (95% CI; n/n) Specificity (95% CI; n/n) 95% (91 to 98; 167/175) 95% (91 to 98; 166/175) 0 6% ( 3 2 to 1 6; 1/175) 3% 3% 98% (96 to 99; 369/376) 98% (97 to 99; 370/376) 0 3% ( 0 7 to 1 5; 1/376)
11 Sens/Spec including or excluding traces Sensitivity Specificity All culture-positive (95% CI; n/n) Smear-negative, culture-positive (95% CI; n/n) All culture-negative (95% CI; n/n) No history of tuberculosis (95% CI; n/n) Xpert 83% (79 86; 383/462) 46% (37 55; 63/137) 98% (97 99; 960/977) 98% (97 99; 715/727) Xpert Ultra 88% (85 91; 408/462) 63% (54 71; 86/137) 96% (94 97; 934/977) 96% (95 98; 701/727) Xpert Ultra, no trace* 86% (82 89; 395/462) 54% (45 63; 74/137) 98% (96 98; 953/977) 98% (96 99; 709/727) Xpert Ultra, conditional trace 88% (85 91; 406/462) 61% (53 70; 84/137) 97% (95 98; 945/977) 96% (95 98; 701/727) Xpert Ultra, trace-repeat 87% (84 90; 404/462) 61% (52 69; 83/137) 97% (95 98; 944/977) 97% (96 98; 707/727)
12 Conclusions Xpert Ultra higher sensitivity in smear-negative PTB May improve early diagnosis in HIV+ patients Children Extrapulmonary TBC Loss in specificity Non-inferiority in Rif resistance detection not met If used as single diagnostic method 2% difference in specificity may lead to considerable over-treatment in medium prevalence settings
Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10
Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10 Introduction Excellent performances, rapid results, and easy to use Questions Where and how are we going
Introduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24
Diagnosis of extrapulmonaryand paediatric tuberculosis AW Dreyer Centre for Tuberculosis NICD Introduction Part of the global efforts to control tuberculosis (TB) include improving case detection, especially
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Dorman S E, Schumacher S G, Alland D, et al.
Assessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
Soedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital There were an estimated 10.4 million new TB cases in 2015, higher than
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
TB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
Incremental cost-effectiveness of the second Xpert MTB/RIF assay to detect Mycobacterium tuberculosis
Original Article Incremental cost-effectiveness of the second Xpert MTB/RIF assay to detect Mycobacterium tuberculosis Guirong Wang, Shuqi Wang, Guanglu Jiang, Yuhong Fu, Yuanyuan Shang, Hairong Huang
of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis
New approaches and the importance of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis Bahrmand.AR, Hadizadeh Tasbiti.AR, Saifi.M, Yari.SH, Karimi.A, Fateh.A, Tuberculosis Dept. Pasteur Institute
World Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2019, Vol. 5, Issue 2, 01-06 Research Article ISSN 2454-2229 WJPLS www.wjpls.org SJIF Impact Factor: 5.008 COMPARATIVE STUDY BETWEEN GENEXPERT MTB/RIF ASSAY AND DIRECT SMEAR MICROSCOPY(DSM) FOR
Toward Solving the Diagnostic Dilemma of Tuberculosis
Toward Solving the Diagnostic Dilemma of Tuberculosis David H. Persing MD, Ph.D. Executive Vice President, Chief Medical and Technology Officer - Cepheid Chief Scientific Officer - Danaher Consulting Professor,
EXPERT GROUP MEETING REPORT
Using the Xpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and rifampicin resistance in adults and children DRUG-RESISTANCE TB/HIV RAPID TB TEST TUBERCULOSIS ACCURACY RECOMMENDATIONS
Comparative performance of emerging rapid diagnostics in HIV-infected individuals
Comparative performance of emerging rapid diagnostics in HIV-infected individuals Maunank Shah M.D. Johns Hopkins University Clinical Diagnostics Research Consortium Background Emerging diagnostics may
: uptake and impact of Xpert MTB/RIF
Photo: Riccardo Venturi 21-215: uptake and impact of Xpert MTB/RIF Wayne van Gemert WHO Global TB Programme, Geneva Joint Partners Forum for Strengthening and Aligning TB Diagnosis and Treatment 27-3 April
Multidrug-Resistant TB
Multidrug-Resistant TB Diagnosis Treatment Linking Diagnosis and Treatment Charles L. Daley, M.D. National Jewish Health University of Colorado Denver Disclosures Chair, Data Monitoring Committee for delamanid
Original Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China
Int J Clin Exp Pathol 2017;10(4):4847-4851 www.ijcep.com /ISSN:1936-2625/IJCEP0045802 Original Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China
Diagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
Urinary TB diagnostics in HIV
Urinary TB diagnostics in HIV SAMRC UCT Eastern Cape collaborative research symposium 20 th October 2017 David Stead Prospective PM study in Zambian tertiary hospital - All medical deaths over 1 year -
Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis
Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis Amit S. Chitnis, MD, MPH; Pennan M. Barry, MD, MPH; Jennifer M. Flood, MD, MPH. California Tuberculosis Controllers
Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance:
Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
Dhanya PR 1*, Shilpa K 2, Manjesh M 3 1, 2
International Journal of Medicine Research ISSN: 2455-7404 Impact Factor: RJIF 5.42 www.medicinesjournal.com Volume 3; Issue 2; April 2018; Page No. 01-05 Study of GeneXpert MTB/RIF for detecting mycobacterium
Xpert MTB/RIF assay validation experience --- impact and plan in China
Xpert MTB/RIF assay validation experience --- impact and plan in China Dr. Zhao Yanlin Chinese Center for Disease Control & Prevention Dr. Richard O Brien FIND April. 16, 2013 Progress Contribution for
Planning for country transition to Xpert MTB/RIF Ultra Cartridges
Planning for country transition to Xpert MTB/RIF Ultra Cartridges Planning for country transition to Xpert MTB/RIF Ultra cartridges April 2017 Contents Acknowledgements About this guide Target audience
TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012
TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children
Report on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
TB infection control: overview and importance
TB infection control: overview and importance John Ferguson, Newcastle, NSW Infectious Diseases & Microbiology jferguson@hnehealth.nsw.gov.au Goroka Hospital, September 2014 Patterns of TB disease Latent
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
National Xpert MTB/RIF Programme
National Xpert MTB/RIF Programme 1. Background to Project This project was initiated at the request of the Honorable Minister of Health, Dr Aaron Motsoaledi, in early 2011, following the World Health Organization
Tuberculosis in children: gaps and opportunities
Tuberculosis in children: gaps and opportunities Mark Nicol Division of Medical Microbiology and Institute for Infectious Diseases and Molecular Medicine, University of Cape Town and National Health Laboratory
Comparative evaluation of diagnostic performance of Xpert between paired IS and GW in children <3.5 years in Cape Town, SA
Comparative evaluation of diagnostic performance of Xpert between paired IS and GW in children
Progress Report March 2016
Progress Report March 2016 Table of Contents Background to project 3 Assays performed to date 3 Correctional Services 5 Peri-Mining 6 Rif Concordance 7 Training: Laboratory and Clinical 7 Challenges identified
Rapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients.
Rapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients. Item Type Thesis Authors Patel, Ravikumar Publisher The University of Arizona. Rights Copyright
Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
New frontiers: Innovation and Access
8th Regional TB Symposium Tashkent, Uzbekistan Prof. L.N. Chernousova Central Tuberculosis Research Institute (CTRI) Ministry of Health of the Republic of Uzbekistan 28 February 1 March, 2019 1970 1975
HIV Clinicians Society Conference TB/HIV Treatment Cascade
HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats
Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
GLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms Revised June 2018 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient
PCR and direct amplification for tuberculosis diagnosis. Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital,
PCR and direct amplification for tuberculosis diagnosis Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital, Paris, France Educational Workshop 05- ECCMID 2015 Copenhagen
Online Annexes (5-8)
2016 Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 1 Contents: Annex 5: GRADE summary of findings
Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm
Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm Kathryn Schnippel 1, Gesine Meyer-Rath 1,2, Lawrence Long 1, Wendy Stevens 3,4, Ian Sanne 1,2, and Sydney Rosen
Heather Alexander, PhD
Xpert MTB/RIF: An Opportunity to Strengthen Laboratory Systems and Bridge the Laboratory-Program Gap Heather Alexander, PhD International Laboratory Branch Division of Global HIV/AIDS Centers for Disease
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
Online Annexes (5-8)
Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs THE END TB STRATEGY Online Annexes (5-8) to WHO
- UPDATE - Implementation and roll-out of Xpert MTB/RIF October 2011
- UPDATE - Implementation and roll-out of Xpert MTB/RIF October 2011 This document provides an update on the global roll-out of Xpert MTB/RIF, the WHO-endorsed test for the rapid and simultaneous detection
Xpert MTB/RIF. implementation manual. Technical and operational how-to : practical considerations IMPLEMENTATION MANUAL TUBERCULOSIS PERFORMANCE
Xpert MTB/RIF implementation manual Technical and operational how-to : practical considerations TB NEW DIAGNOSTIC TESTS IMPLEMENTATION MANUAL DRUG-RESISTANCE TB/HIV RAPID TB TEST TUBERCULOSIS ACCURACY
Original Article ROLE OF GENE EXPERT/MTB TEST IN CHILDHOOD TUBERCULOSIS
Original Article 1 2 Aisha Sajid, Sohaib Riaz 1 Associate Professor/HOD Pediatrics University Medical and Dental College, Madinah Teaching Hospital 2 Assistant Professor Pediatrics, University Medical
Role of Xpert MTB/RIF Assay in the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance
Role of Xpert MTB/RIF Assay in the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance Taher Abdel -Aziz 1, Naglaa Azab 2, Eman AboElabass 3 & I.M El-deen 4 1 Ph.D of Biochemistry, Faculty of
Diagnosis of HIV-Associated Tuberculosis
Diagnosis of HIV-Associated Tuberculosis Stephen D. Lawn Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine University of Cape Town Dept. Of Clinical Research, Faculty of Infectious
Target product profiles for next generation TB diagnostics. Claudia Denkinger, MD PhD MSc Head of TB, FIND
Target product profiles for next generation TB diagnostics Claudia Denkinger, MD PhD MSc Head of TB, FIND 29 th October 2014 The Global TB Epidemic Undiagnosed TB Undiagnosed TB Facts: 9 million TB cases
Progress Report July 2014
Progress Report July 2014 Table of Contents Background to project 3 Assays performed to date 5 Rif Concordance 8 Errors 8 Monthly uptake since implementation started 10 Specific GeneXpert Site Progress
New Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
GLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms March 2017 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient access
Diagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology: A Short Review
International Journal of Advanced Microbiology and Health Research www.ijamhr.com Volume 1; Issue 1; September 2017; Page No. 20-24 Review Article Diagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology:
Virtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine
Virtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine 3rd sector OR and developing countries 27th March 2013, London School of Economics
Gene Xpert for Direct Detection of Mycobacterium Tuberculosis in Stool Specimens from Children with Presumptive Pulmonary Tuberculosis
198 Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 46, no. 2, 2016 Gene Xpert for Direct Detection of Mycobacterium Tuberculosis in Stool Specimens from Children
NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL
NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL Susan Novak-Weekley, S(M), ASCP, Ph.D., D(ABMM) Director of Microbiology,
Xin-Feng Wang 1, Jun-Li Wang 2, Mao-Shui Wang 1. Introduction
Original Article Page 1 of 6 Evaluation of GenoType MTBDRplus assay for rapid detection of isoniazid- and rifampicin-resistance in Mycobacterium tuberculosis isolates from diabetes mellitus patients Xin-Feng
Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
How best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
INTENSIFIED TB CASE FINDING
INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities
2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:
The theme for World TB Day 2014 is Reach the missed 3 million. Every year 3 million people who fall ill with TB are missed by health systems and do not always get the TB services that they need and deserve.
TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
Diagnosis of tuberculosis in children H Simon Schaaf
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
Articles. Heather J Zar, Lesley Workman, Washiefa Isaacs, Keertan Dheda, Widaad Zemanay, Mark P Nicol
Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of on respiratory specimens: a prospective study Heather J Zar, Lesley Workman, Washiefa Isaacs, Keertan Dheda,
MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
Costs of Novel Tuberculosis Diagnostics Will Countries Be Able to Afford It?
SUPPLEMENT ARTICLE Costs of Novel Tuberculosis Diagnostics Will Countries Be Able to Afford It? Andrea Pantoja, 1 Sandra V. Kik, 2 and Claudia M. Denkinger 3 1 Independent consultant for FIND, Zürich,
Online Annexes (2-4)
Online Annexes (2-4) to WHO Policy update: The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin THE END TB STRATEGY Online Annexes (2-4) to WHO Policy update:
Health Care Worker Training on Roll Out New TB Diagnostic Test. Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)
Health Care Worker Training on Roll Out New TB Diagnostic Test Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien) Overview Specimen Collection Investigations to request Sorting & registering
Pediatric Drug-Resistant TB in China
Pediatric Drug-Resistant TB in China Shuihua Lu,Tao Li Shanghai Public Health Clinical Center Jan.18,2013 A MDR-TB CASE A four and a half years old boy, spent 4 yeas of his life in hospital. His childhood
TB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
Challenges in the Diagnosis of Extrapulmonary Tuberculosis: Role of Gene Xpert Mycobacterium Tuberculosis/Rifampicin Assay
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/499 Challenges in the Diagnosis of Extrapulmonary Tuberculosis: Role of Gene Xpert Mycobacterium Tuberculosis/Rifampicin
TB FIT Modelling. 24th Annual PhilCAT Convention. Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017
TB FIT Modelling 24th Annual PhilCAT Convention Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017 TB-FIT - Objectives 1. Develop a computer model of patient pathways for diagnosis
New Tuberculosis Guidelines. Jason Stout, MD, MHS
New Tuberculosis Guidelines Jason Stout, MD, MHS Two New Sets of Guidelines Treatment of Drug-Susceptible Tuberculosis Clinical Infectious Diseases 2016; 63(7): e147-e195 Diagnosis of Tuberculosis in Adults
Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health
Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Churchyard GJ, Stevens WS, Mametja LD, et al.
A pilot study measuring the kinetic profile of IP-10 over the first 14 days of PTB chemotherapy
A pilot study measuring the kinetic profile of IP-10 over the first 14 days of PTB chemotherapy Dr Rachel Saunders Dr Matthew Blakiston Liverpool School of Tropical Medicine Background TB is responsible
Experience with implementation of Xpert MTB/RIF in India. Dr K S Sachdeva Addl. DDG (TB), Government of India
Experience with implementation of Xpert MTB/RIF in India Dr K S Sachdeva Addl. DDG (TB), Government of India Background Two ongoing projects being implemented in India, under RNTCP by FIND Gene Xpert feasibility
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Lancelot Pinto is a
A retrospective evaluation study of diagnostic accuracy of Xpert MTB/RIF assay, used for detection of Mycobacterium tuberculosis in Greece
Örebro University School of Health and Medical Science Biomedical Laboratory Science Programme 180 credits Degree project in biomedical laboratory science, advanced course, 15 credits May 21, 2015 A retrospective
Overview of the Presentation
Overview of the Presentation Definitions(TBCase, MDR-TB & XDR-TB) Global Tuberculosis (TB,HIV/TB,MDR & XDR)Scenario & Trend Risk factor for TB Natural history of TB Types of TB & Trends of Extra Pulmonary
The clinical utility of the urine based lateral flow lipoarabinomannan (LF-LAM) assay in HIV infected adults in Myanmar.
The clinical utility of the urine based lateral flow lipoarabinomannan (LF-LAM) assay in HIV infected adults in Myanmar Josh Hanson Background Tuberculosis is the commonest cause of death in HIV infected
Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012
Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How
Akansha Arora*, Anil Jain, B. S. Karnawat, Rakesh Kumawat
International Journal of Contemporary Pediatrics Arora A et al. Int J Contemp Pediatr. 2018 Jul;5(4):1609-1613 http://www.ijpediatrics.com pissn 2349-3283 eissn 2349-3291 Original Research Article DOI:
Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review
Maynard-Smith et al. BMC Infectious Diseases (2014) 14:709 DOI 10.1186/s12879-014-0709-7 RESEARCH ARTICLE Open Access Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis
International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007
TB Along the US/Mexico Border El Paso, Texas August 22-23, 2007 International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007 Barbara J Seaworth MD Medical Director Heartland National
Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011
Tropical Medicine and International Health doi:10.1111/tmi.12183 volume 00 no 00 Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011 Nathan Kapata 1,2,3,5, Pascalina Chanda-Kapata
Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work
Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection Results of Group Work DOTS expansion and enhancement Objective This group deals with the majority
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman*, Samuel G Schumacher*, David Alland, Pamela
MAJOR ARTICLE. feces; Mycobacterium tuberculosis; Xpert MTB/RIF.
MAJOR ARTICLE Detection of Mycobacterium tuberculosis (MTB) in Fecal Specimens From Adults Diagnosed With Pulmonary Tuberculosis Using the Xpert MTB/ Rifampicin Test Hiroyuki Kokuto, 1 Yuka Sasaki, 1 Shoji
Molecular assays in Tuberculosis. Jatin Yegurla Junior resident
Molecular assays in Tuberculosis Jatin Yegurla Junior resident 17-3-2018 Contents Introduction TB-PCR Line Probe assay (LPA) GenoType MTBDRsl test (Second line LPA) Xpert MTB/RIF (GeneXpert) (CB-NAAT)
APPLICATION OF IMMUNO CHROMATOGRAPHIC METHODS IN PLEURAL TUBERCULOSIS
APPLICATION OF IMMUNO CHROMATOGRAPHIC METHODS IN PLEURAL TUBERCULOSIS Hadizadeh Tasbiti.AR, Yari.SH, Bahrmand.AR, Karimi.A,Fateh.A, Sayfi.M Tuberculosis Dept.Pasteur Institute of Iran.Tehran.Iran 1 INTRODUCTION
lymphadenitis from Fine Needle Aspiration biopsy specimens
JCM Accepts, published online ahead of print on 31 August 2011 J. Clin. Microbiol. doi:10.1128/jcm.01310-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
Role of gene Xpert MTB/RIF in diagnosis of Extrapulmonary Tuberculosis at Government Medical College, Amritsar
International Journal of Current Research in Medical Sciences ISSN: 2454-5716 P-ISJN: A4372-3064, E -ISJN: A4372-3061 www.ijcrims.com Original Research Article Volume 4, Issue 3-2018 DOI: http://dx.doi.org/10.22192/ijcrms.2018.04.03.017
Improved diagnosis of extrapulmonary tuberculosis by antigen detection using immunochemistry-based assay. Tehmina Mustafa
Improved diagnosis of extrapulmonary tuberculosis by antigen detection using immunochemistry-based assay Tehmina Mustafa Overview Introduction: extrapulmonary tuberculosis (TB) & diagnostic challenges
Evaluation of the Xpert MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia
Mavenyengwa et al. Infectious Diseases of Poverty (2017) 6:13 DOI 10.1186/s40249-016-0213-y SHORT REPORT Open Access Evaluation of the Xpert MTB/RIF assay and microscopy for the diagnosis of Mycobacterium
What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
TB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant